

Xspray Pharma appoints Chief Operating Officer and changes the Management Team

Xspray Pharma has appointed Niklas Adenborg as the company's CFO (Chief Financial Officer) and Linda Glimberg as the company's COO (Chief Operating Officer), a newly established role. Both are already part of the Xspray Pharma team; Niklas Adenborg as Finance Director and Linda Glimberg as consulting Senior Vice President Legal. Both will be part of Xspray Pharma's executive management team, whose work in the future will be coordinated by Linda Glimberg in the role as COO.

The newly established role as COO includes responsibilities such as coordination of management functions, legal issues, compliance and supply chain management. Linda Glimberg will take up her position as COO on June 1, 2024 and Niklas Adenborg will take up his position as CFO on July 1, 2024.

"Xspray Pharma is building up momentum this year in order to transform from a research and development company to a commercial life science company. I am pleased to be able to strengthen the management by the internal recruitments of two highly competent individuals that will take on greater responsibilities as we now enter into this new and exciting phase for the company," says Xspray Pharma's CEO Per Andersson.

Niklas Adenborg has extensive finance and auditing experience, and has previously been auditor at KPMG. Niklas was employed by Xspray Pharma in 2019 and currently holds the position as Finance Director. Linda Glimberg has extensive legal experience including in relation to life science. Linda has during the past few years managed her own consulting business focusing on business law, compliance and the provision of structure and strategic advice to small and mid-sized life science companies. She has broad prior experience from different listed companies and sectors, including the role as VP & Corporate Counsel at Husqvarna.

The current Interim CFO will be leaving the company when his assignment has been completed.

For further information, please contact:

Kerstin Hasselgren
Senior Advisor & Investor Relations
Xspray Pharma AB
Mob: +46 (0) 70 311 16 83
E-mail: kerstin.hasselgren@xspray.com

About Xspray Pharma

About Xspray Pharma AB

Xspray Pharma AB (publ) is a pharmaceutical company focused on the development of improved PKIs for cancer treatment, leveraging its proprietary HyNap™ technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Xspray Pharma's shares are traded at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). For more information about Xspray Pharma AB and its innovative approach to cancer treatment, please visit www.xspraypharma.com.

Attachments

[Xspray Pharma appoints Chief Operating Officer and changes the Management Team](#)